Sanford C. Bernstein Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $921.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target reduced by Sanford C. Bernstein from $925.00 to $921.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price objective suggests a potential upside of 19.95% from the stock’s current price.

A number of other research analysts have also recently commented on the company. Barclays initiated coverage on Regeneron Pharmaceuticals in a research note on Friday, March 6th. They issued an “overweight” rating and a $923.00 target price on the stock. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Finally, Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their target price for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $810.78.

Regeneron Pharmaceuticals Stock Down 1.0%

REGN opened at $767.85 on Wednesday. The stock has a market cap of $81.18 billion, a PE ratio of 18.48, a P/E/G ratio of 2.05 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The business’s fifty day simple moving average is $767.27 and its 200 day simple moving average is $717.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $12.07 earnings per share. As a group, research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 3,774 shares of company stock valued at $2,942,738. 7.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Insigneo Advisory Services LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares during the period. Guardian Wealth Advisors LLC NC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 15 shares during the period. MCF Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Finally, Rexford Capital Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 5.5% during the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.